Spark Therapeutics' vision-loss gene therapy to cost $850,000 per patient

(Reuters) - Spark Therapeutics Inc said on Wednesday it would charge $850,000 per patient for its gene therapy to treat a rare form of blindness, lesser than analysts' expectation of around $1 million.